Social functioning: Specific ‐ unemployed ‐ at about 1 year · patients with schizophrenia
ANY FAMILY BASED INTERVENTIONS (>5 sessions) showed no clear difference in social functioning: Specific ‐ unemployed ‐ at about 1 year compared with STANDARD CARE (low certainty).
1 finding from 1 review
Social functioning: Specific ‐ unable to live independently ‐ at about 1 year · patients with schizophrenia
ANY FAMILY BASED INTERVENTIONS (>5 sessions) showed no clear difference in social functioning: Specific ‐ unable to live independently ‐ at… compared with STANDARD CARE (low certainty).
1 finding from 1 review
Family outcome: Burden ‐ not improved/worse (objective burden related to self‐sufficiency) · patients with schizophrenia
It is very uncertain whether ANY FAMILY BASED INTERVENTIONS (>5 sessions) changes family outcome: Burden ‐ not improved/worse (objective burden… compared with STANDARD CARE (very low certainty).
1 finding from 1 review
Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · patients with schizophrenia
1 finding from 1 review
Behaviour: No clinically important response (as defined by the original studies) · patients with schizophrenia
1 finding from 1 review
Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · patients with schizophrenia
1 finding from 1 review
Global state: No clinically important response (as defined by the original studies) · patients with schizophrenia
1 finding from 1 review
Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication · patients with schizophrenia
ZOTEPINE showed no clear difference in adverse effects: Extrapyramidal effects ‐ use of antiparkinson… compared with REMOXIPRIDE (low certainty).
1 finding from 1 review
Behaviour: No clinically important response (as defined by the original studies) · patients with schizophrenia
1 finding from 1 review
Global state: No clinically important response (as defined by the original studies) · patients with schizophrenia
It is very uncertain whether ZOTEPINE changes global state: No clinically important response (as defined by the… compared with CLOZAPINE (very low certainty).
1 finding from 1 review
Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication · patients with schizophrenia
It is very uncertain whether ZOTEPINE changes adverse effects: Extrapyramidal effects ‐ use of antiparkinson… compared with CLOZAPINE (very low certainty).
1 finding from 1 review
Behaviour: No clinically important response (as defined by the original studies) · patients with schizophrenia
1 finding from 1 review
Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · patients with schizophrenia
2 findings from 1 review
Global state: No clinically important response (as defined by the original studies) · patients with schizophrenia
1 finding from 1 review
Adverse effects: Extrapyramidal effects ‐ use of antiparkinson medication ‐ vs 4mg risperidone · patients with schizophrenia
It is very uncertain whether ZOTEPINE changes adverse effects: Extrapyramidal effects ‐ use of antiparkinson… compared with RISPERIDONE (very low certainty).
1 finding from 1 review
Adverse effects: Extrapyramidal effects ‐ use of antiparkinson medication ‐ vs 8mg risperidone · patients with schizophrenia
It is very uncertain whether ZOTEPINE changes adverse effects: Extrapyramidal effects ‐ use of antiparkinson… compared with RISPERIDONE (very low certainty).
1 finding from 1 review
Weight (kg) · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review
Weight: 2a. BMI ‐ Increase · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
It is very uncertain whether SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN changes weight: 2a. BMI ‐ Increase compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (very low certainty).
1 finding from 1 review
Physiological measures: 1c. Average fasting glucose change ‐ switching to aripiprazole and quetiapine · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review
Relapse · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN showed no clear difference in global state: Relapse compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (low certainty).
1 finding from 1 review